Liontrust Investment Partners’s Barinthus Biotherapeutics BRNS Stock Holding History

Liontrust Investment Partners’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-133,918	Closed	-$276K	–	195
2023 Q2	$276K	Sell	133,918 -321,930	-71%	-$762K	﹤0.01%	203
2023 Q1	$1.02M	Sell	455,848 -144,152	-24%	-$401K	0.02%	177
2022 Q4	$1.43M	Hold	600,000	–	–	0.03%	148
2022 Q3	$1.9M	Hold	600,000	–	–	0.03%	195
2022 Q2	$2.67M	Hold	600,000	–	–	0.04%	186
2022 Q1	$3.12M	Hold	600,000	–	–	0.04%	141
2021 Q4	$6.67M	Hold	600,000	–	–	0.08%	120
2021 Q3	$9.44M	Buy	+600,000	New	+$9.11M	0.13%	87

Other funds holding BRNS

M&G Investment Management London, United Kingdom $28.2B AUM 25.87% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

BlueCrest Capital Management St Helier, Jersey $1.06B AUM 20.01% 1-Year Est. Return

Baird Financial Group

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return

Ipswich Investment Management Beverly, Massachusetts $426M AUM 24.58% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return